Emerging role of the bufadienolides in cardiovascular and kidney diseases

American Journal of Kidney Diseases

Volumn 56, Issue 2, 2010, Pages 359-370

  Puschett, Jules B ^a   Agunanne, Enoch ^a   Uddin, Mohammad N ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Bufadienolides; hypertension; marinobufagenin; pre eclampsia; resibufogenin

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; BUFADIENOLIDE DERIVATIVE; BUFALIN; BUFOGENIN; CARDENOLIDE; DIGITALIS; MARINOBUFAGENIN; MITOGEN ACTIVATED PROTEIN KINASE; ROSTAFUROXIN; SPIRONOLACTONE; SYNAPTOPHYSIN; TELOCINOBUFAGIN; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; CYTOKINE; VASOCONSTRICTOR AGENT;

ADULT; ANEMIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CASE REPORT; CELL MATURATION; CELL PROLIFERATION; CLINICAL TRIAL; CREATININE CLEARANCE; ESSENTIAL HYPERTENSION; EXTRACELLULAR FLUID; FEMALE; FETUS DISTRESS; HEART MUSCLE FIBROSIS; HEMATOCRIT; HUMAN; HYPERTENSION; KIDNEY DISEASE; OLIGOHYDRAMNIOS; PREECLAMPSIA; PREGNANCY TERMINATION; PROTEINURIA; REVIEW; SODIUM EXCRETION; URINALYSIS; URINARY EXCRETION; URINE; VASOCONSTRICTION; ANIMAL; BLOOD; BLOOD VOLUME; CAPILLARY PERMEABILITY; CHEMICAL STRUCTURE; CHEMISTRY; CHRONIC KIDNEY FAILURE; HEART DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; VASCULAR RESISTANCE;

ANIMALS; BLOOD VOLUME; BUFANOLIDES; CAPILLARY PERMEABILITY; CARDIOTONIC AGENTS; CYTOKINES; FEMALE; HEART DISEASES; HUMANS; HYPERTENSION; MOLECULAR STRUCTURE; PRE-ECLAMPSIA; PREGNANCY; RENAL INSUFFICIENCY, CHRONIC; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 77955905058     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.01.023     Document Type: Article

References (98)

1. W. Schoner Endogenous cardiac glycosides, a new class of steroid hormones Eur J Biochem. 269 2002 2440 2448
2. W. Schoner, and G. Scheiner-Bobis Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer Semin Nephrol. 25 2005 343 351
3. W. Schoner, and G. Scheiner-Bobis Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am J Physiol Cell Physiol. 293 2007 509 536
4. S. Bova, M.P. Blaustein, J. Ludens, D. Harris, D. DuCharme, and J.M. Hamlyn Effect of an endogenous ouabainlike compound on heart and aorta Hypertension 17 6 1991 944 950
5. H. Ooi, and W. Colucci Pharmacological treatment of heart failure J.E. Hardman, L.E. Limbird, A.G. Gilman, Goodman and Gilman's Pharmacological Basis of Therapeutics 10th ed. 2001 McGraw-Hill New York, NY 901 932
6. X.C. Ma, B.J. Zhang, and X.L. Xin, et al. Simultaneous quantification of seven major bufadienolides in three traditional Chinese medicinal preparations of Chan Su by HPLC-DAD Nat Prod Commun. 4 2 2009 179 184
7. R.I. Dmitrieva, A.Y. Bagrov, E. Lalli, P. Sassone-Corsi, D.M. Stocco, and P.A. Doris Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by a pathway that is independent of cholesterol side-chain cleavage Hypertension 36 2000 442 448
8. P.J. Hilton, R.W. White, and G.A. Lord, et al. An inhibitor of the sodium pump obtained from human placenta Lancet 348 1996 303 305
9. A.Y. Bagrov, N.I. Agalakova, V.A. Kashkin, and O.V. Fedorova Endogenous cardiotonic steroids and differential patterns of sodium pump inhibition in NaCl-loaded salt-sensitive and normotensive rats Am J Hypertens. 22 5 2009 559 563
10. H.V. Vu, M.R. Ianosi-Irimie, and C.A. Pridjian, et al. Involvement of marinobufagenin in a rat model of human preeclampsia Am J Nephrol. 25 5 2005 520 528
11. G. Blanco, and R.W. Mercer Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function Am J Physiol Renal Physiol. 275 1998 F633 F650
12. A.Y. Bagrov, J.I. Shapiro, and O.V. Fedorova Endogenous cardiotonic steroids physiology, pharmacology, and novel therapeutic targets Pharmacol Rev. 61 1 2009 9 38
13. M. Liang, J. Tian, and L. Liu, et al. Identification of a pool of non-pumping Na/K-ATPase J Biol Chem. 282 14 2007 10585 10593
14. H. Wang, M. Haas, and M. Liang, et al. Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase J Biol Chem. 23 17 2004 17250 17259 279
15. J.M. Hamlyn, M.P. Blaustein, and S. Bova, et al. Identification and characterization of a ouabain-like compound from human plasma Proc Natl Acad Sci U S A 88 1991 6259 6263
16. J.H. Ludens, M.A. Clark, and D.W. DuCharme, et al. Purification of an endogenous digitalis like factor from human plasma for structural analysis Hypertension 17 1991 923 929
17. A. Goto, T. Ishiguro, and K. Yamada, et al. Isolation of a urinary digitalis-like factor indistinguishable from digoxin Biochem Biophys Res Commun. 173 1990 1093 1101
18. A.A. Tymiak, J.A. Norman, and M. Bolgar, et al. Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus Proc Natl Acad Sci U S A 90 1993 8189 8193
19. Y. Komiyama, N. Nishimura, and M. Munakata, et al. Identification of endogenous ouabain in culture supernatant of PC12 cells J Hypertens. 19 2001 229 236
20. L. Krenn, and B. Kropp Bufadienolides from animal and plant sources Phytochemistry 48 1 1998 1 29
21. D. Lichtstein, I. Gati, and S. Samuelov, et al. Identification of digitalis like compounds in human cataractous lenses Eur J Biochem. 216 1993 261 268
22. A.Y. Bagrov, and O.V. Fedorova Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+, K+-pump in human mesenteric arteries J Hypertens. 16 1998 1953 1958
23. Y. Komiyama, X.H. Dong, and N. Nishimura, et al. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure Clin Biochem. 38 2005 36 45
24. D.A. Lopatin, E.K. Ailamazian, and R.I. Dmitrieva, et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia J Hypertens. 17 1999 1179 1187
25. L.K. Dahl, K.D. Knudsen, M. Heine, and G. Leitl Effects of chronic excess salt ingestion. Genetic influence on the development of salt hypertension in parabiotic rats. Evidence for a circulating factor J Exp Med. 126 1967 687 699
26. H.E. deWardener, and E.M. Clarkson Concept of natriuretic hormone Physiol Rev. 65 1985 658 759
27. M.P. Blaustein Sodium ions, calcium ions, blood pressure regulation and hypertension A reassessment and a hypothesis Am J Physiol. 232 1977 C167 C173
28. J.M. Hamlyn, R. Ringel, and J. Schaeffer, et al. A circulating inhibitor of (Na+K)-ATPase associated with essential hypertension Nature 300 1982 650 652
29. 2+ stores and cell responsiveness Am J Physiol. 264 1993 C1367 C1387
30. A.C. Guyton Physics of blood, blood flow, and pressure: hemodynamics A.C. Guyton, Textbook of Medical Physiology 7th ed. 1986 WB Saunders Company Philadelphia, PA 206 217
31. J.H. Laragh, J.E. Sealey, A.P. Niarchos, and T.G. Pickering The vasoconstriction-volume spectrum in normotension and in the pathogenesis of hypertension Fed Proc. 41 1982 2415 2423
32. J.H. Laragh, R.L. Letcher, and T.G. Pickering Renin profiling for diagnosis and treatment of hypertension JAMA 241 2 1979 151 156
33. D. Zhao, D.M. Seth, and L.G. Navar Enhanced distal nephron sodium reabsorption in chronic angiotensin II-infused mice Hypertension 54 1 2009 120 126
34. C.T. Wang, S.Y. Chin, and L.G. Navar Impairment of pressure-natriuresis and renal authoregulation in ANG II-infused hypertensive rats Am J Physiol Renal Physiol. 279 2000 F319 F325
35. M.H. Weinberger Sodium and blood pressure 2003 Curr Opin Cardiol. 19 2004 353 356
36. P. Meneton, X. Jeunemaitre, H.E. deWardener, and G.A. MacGregor Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases Physiol Rev. 85 2005 679 715
37. O.V. Fedorova, N.I. Kolodkin, N.I. Agalakova, E.G. Lakatta, and A.Y. Bagrov Marinobufagenin, an endogenous α-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats Hypertension 37 2 2001 462 466
38. O.V. Fedorova, N.I. Kolodkin, and N.I. Agalakova, et al. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake J Hypertens. 23 2005 835 842
39. O.V. Fedorova, M.I. Talan, N.I. Agalakova, E.G. Lakatta, and A.Y. Bagrov Endogenous ligand of α1 sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension Circulation 105 2002 1122 1127
40. M.B. Pamnani, S. Chen, and H.J. Bryant, et al. Effects of three sodium-potassium adenosine triphosphatase inhibitors Hypertension 18 1991 316 324
41. M.B. Pamnani, S. Chen, C.M. Yuan, and F.J. Haddy Chronic blood pressure effects of bufalin, a sodium-potassium ATPase inhibitor, in rats Hypertension 23 suppl I 1994 I-106 I-109
42. S. Ahmad, M. Kenny, and B.H. Scribner Hypertension and a digoxin-like marker in the plasma of dialysis patients: possible marker for a natriuretic hormone Clin Physiol Biochem. 4 3 1986 210 216
43. D.A. Wright, G.A. Lord, R.W. White, M.J. Hilton, D.B. Gordon, and P.J. Hilton Evidence for circulating bufenolide in a volume-expanded patient Lancet 350 9075 1997 409
44. H.C. Gonick, Y. Ding, N.D. Vaziri, A.Y. Bagrov, and O.V. Fedorova Simultaneous measurement of marinobufagenin, ouabain, and hypertension- associated protein in various disease states Clin Exp Hypertens. 20 5&6 1998 617 627
45. I.V. Averina, N.I. Tapilskaya, and V.A. Reznik, et al. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia Cell Mol Biol. 52 8 2006 19 23
46. A.I. Fridman, S.A. Matveev, N.I. Agalakova, O.V. Fedorova, E.G. Lakatta, and A.Y. Bagrov Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity J Hypertens. 20 2002 1189 1194
47. H. Vu, M. Ianosi-Irimie, and S. Danchuk, et al. Resibufogenin corrects hypertension in a rat model of human preeclampsia Exp Biol Med. 231 2006 215 220
48. D. Horvat, J. Severson, M. Uddin, B. Mitchell, and J.B. Puschett Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome Hypertens Pregnancy 29 1 2010 1 9
49. S. Danchuk, S. Sukhanov, D. Horvat, M.N. Uddin, and J.B. Puschett Effects of resibufogenin in experimental hypertension Am J Nephrol. 28 2008 8 13
50. O.V. Fedorova, A.S. Simbirtsev, and N.I. Kolodkin, et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension J Hypertens. 26 2008 2414 2425
51. G. Pridjian, and J.B. Puschett Preeclampsia, part I: clinical and pathophysiological considerations Obstet Gynecol Surv. 57 2002 598 618
52. G. Pridjian, and J.B. Puschett Preeclampsia, part II: experimental and genetic considerations Obstet Gynecol Surv. 57 2002 619 640
53. J.M. Roberts, R.N. Taylor, T.J. Musci, G.M. Rodgers, C.A. Hubel, and M.K. McLaughlin Preeclampsia: an endothelial cell disorder Am J Obstet Gynecol. 161 1989 1200 1204
54. J.B. Puschett The role of excessive volume expansion in the pathogenesis of preeclampsia Med Hypotheses 67 2006 1125 1132
55. M.L. Tjoa, R.J. Levine, and S.A. Karumanchi Angiogenic factors in preeclampsia Front Biosci. 12 2007 2395 2402
56. 1 receptor J Clin Invest. 103 7 1999 945 952
57. D.E. Scott Anemia in pregnancy Obstet Gynecol Annu. 1 1972 219 244
58. M. Ianosi-Irimie, H.V. Vu, and J. Whitbred, et al. A rat model of preeclampsia Clin Exp Hypertens. 8 2005 605 617
59. G.St.J. Whitley, and J.E. Cartwright Trophoblast-mediated spiral artery remodeling: a role for apoptosis J Anat. 215 2009 21 26
60. H.L. Lamarca, C.A. Morris, G.R. Pettit, T. Nagowa, and J.B. Puschett Marinobufagenin impairs first trimester cytotrophoblast differentiation Placenta 27 2006 984 988
61. M.N. Uddin, D. Horvat, and S.S. Glaser, et al. Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells Placenta 29 2008 266 273.
62. E.R. Nortwitz, D.J. Schust, and S.J. Fisher Implantation and the survival of early pregnancy N Engl J Med. 345 19 2001 1400 1408
63. R. Pijnenbort, G. Dixon, W.B. Robertson, and I. Brosens Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy Placenta 1 1980 3 19
64. E. Agunanne, D. Horvat, M.N. Uddin, and J. Puschett The treatment of preeclampsia in a rat model employing Digibind.® Am J Perinatol. 27 4 2010 299 305
65. E.D. Freis, and J.F. Kenny Plasma volume, total circulating protein, and "available fluid" abnormalities in preeclampsia and eclampsia J Clin Invest. 27 2 1948 283 289
66. D.E. Scott, and J.A. Pritchard Iron deficiency in healthy young college women JAMA 199 12 1967 147 150
67. D.M. Campbell, and A.J. Campbell Evans blue disappearance rate in normal and preeclamptic pregnancy Clin Exp Hypertens. 2 1983 163 169
68. R. Hayman, J. Brockelsby, L. Kenny, and P. Baker Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor J Soc Gynecol Invest. 6 1999 3 10
69. M.N. Uddin, L.B. McLean, and F.A. Hunter, et al. Vascular leak in a rat model of preeclampsia Am J Nephrol. 30 1 2009 26 33
70. M.N. Uddin, D. Horvat, E.W. Childs, and J.B. Puschett Marinobufagenin causes endothelial cell monolayer hyperpermeability by altering apoptotic signaling Am J Physiol Regul Integr Comp Physiol. 296 6 2009 R1726 R1734
71. M.A. Brown, E.D.M. Gallery, M.R. Ross, and R.P. Esber Sodium excretion in normal and hypertensive pregnancy: a prospective study Am J Obstet Gynecol. 159 2 1988 297 307
72. L.C. Chesley The renal excretion of sodium in women with preeclampsia Clin Obstet Gynecol. 1 2 1958 317 323
73. S.E. Maynard, J. Min, and J. Merchan, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest. 111 5 2003 649 658
74. F.G. Cunningham, J.C. Hauth, K.J. Leveno, L. Gilstrap, S.L. Bloom, and K.D. Wenstrom Hypertensive disorders in pregnancy F.G. Cunningham, J.C. Hauth, K.J. Leveno, L. Gilstrap, S.L. Bloom, K.D. Wenstrom, Williams Obstetrics 22nd ed. 2005 McGraw-Hill New York, NY 761 808
75. L.C. Chesley, C. Valenti, and H. Rein Excretion of sodium loads by nonpregnant and pregnant normal, hypertensive and pre-eclamptic women Metabolism VII 5 1958 575 588
76. C.R. Parker Jr, R.B. Everett, P.J. Whalley, J.G. Quirk Jr, N.F. Gant, and P.C. MacDonald Hormone production during pregnancy in the primigravid patient II. Plasma levels of deoxycorticosterone throughout pregnancy of normal women and women who developed pregnancy-induced hypertension Am J Obstet Gynecol. 138 1980 626 631
77. M.N. Uddin, D. Horvat, S.S. Glaser, B.M. Mitchell, and J.B. Puschett Examination of the cellular mechanisms by which marinobufagenin inhibits cytotrophoblast function J Biol Chem. 283 26 2008 17946 17953
78. Y. Johnson, M. Rubèr, and L. Matthiesen, et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies J Reprod Immunol. 70 2006 83 91
79. J.H. Tinsley, V.L. Chiasson, S. South, A. Mahajan, and B.M. Mitchell Immunosuppression improves blood pressure and endothelial function in a rat model of pregnancy-induced hypertension Am J Hypertens. 22 10 2009 1107 1114
80. A. Enomoto, M.C. Rho, K. Komiyama, and M. Hayashi Inhibitory effects of bufadienolides on interleukin-6 in MH-60 cells J Nat Prod. 67 2004 2070 2072
81. M. Hayashi, M.C. Rho, and A. Fukami, et al. Biological activity of a novel nonpeptide antagonist to the interleukin-6 receptor 20S, 21-epoxy-resibufogenin-3-formate J Pharmacol Exp Ther. 303 2002 104 109
82. A. Enomoto, M.C. Rho, A. Fukami, O. Hiraku, K. Komiyama, and M. Hayashi Suppression of cancer cachexia by 20S, 21-epoxy-resibufogenin-3-acetate - a novel nonpeptide IL-6 receptor antagonist Biochem Biophys Res Commun. 323 2004 1096 1102
83. P. Terness, D. Navolan, C. Dufter, B. Kopp, and G. Opelz The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity Int Immunopharmacol. 1 2001 119 134
84. P. Ferrari, M. Ferrandi, G. Valentini, and G. Bianchi Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+-ATPase alterations in ouabain and adducin-dependent hypertension Am J Physiol Regul Integr Comp Physiol. 290 2006 R529 R535
85. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth, et al. Kidney disease as a risk factor for development of cardiovascular disease A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2003 2154 2169
86. R.M. Henry, P.J. Kostense, and G. Bos, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study Kidney Int. 62 2002 1402 1407
87. USRDS Excerpts from the US Renal Data System, 2007 Annual Data Report, Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Am J Kidney Dis. 51 suppl 1 2008 S137 S154
88. S. Priyadarshi, B. Valentine, and C. Han, et al. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat Kidney Int. 63 2003 1785 1790
89. D.J. Kennedy, J. Elkareh, and A. Shidyak, et al. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse Am J Physiol Renal Physiol. 294 2008 F450 F454
90. D.J. Kennedy, S. Vetteth, and S.M. Periyasamy, et al. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy Hypertension 47 2006 488 495
91. J. Elkareh, D.J. Kennedy, and B. Yashaswi, et al. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy Hypertension 49 2007 215 224
92. J. Elkareh, S.M. Periyasamy, and A. Shidyak, et al. Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy Am J Physiol Renal Physiol. 296 2009 F1219 F1226
93. J. Tian, A. Shidyak, and S.M. Periyasamy, et al. Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin Hypertension 54 2009 1313 1320
94. L.V. Fedorova, V. Raju, and N. El-Okdi, et al. The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition Am J Physiol Renal Physiol. 296 2009 F922 F934
95. A.A. Eddy Molecular basis of renal fibrosis Pediatr Nephrol. 15 2000 290 301
96. H. Okada, and R. Kalluri Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis Curr Mol Med. 5 2005 467 474
97. M. Zeisberg, and R. Kalluri Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis Front Biosci. 13 2008 6991 6998
98. F. Strutz, H. Okada, and C.W. Lo, et al. Identification and characterization of a fibroblast marker: FSP1 J Cell Biol. 130 2 1995 393 405